Amplify Debuts New Weight Loss Drug ETF
On Tuesday, Amplify entered the weight loss ETF space with the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR). THNR operates with a net expense ratio of 0.59%. Additionally, the fund aims to provide investors with results similar to the performance of the VettaFi Weight Loss Drug & Treatment Index (THINR). THINR [...]
The post Amplify Debuts New Weight Loss Drug ETF appeared first on ETF Trends.
Welcome to Billionaire Club Co LLC, your gateway to a brand-new social media experience! Sign up today and dive into over 10,000 fresh daily articles and videos curated just for your enjoyment. Enjoy the ad free experience, unlimited content interactions, and get that coveted blue check verification—all for just $1 a month!
Account Frozen
Your account is frozen. You can still view content but cannot interact with it.
Please go to your settings to update your account status.
Open Profile Settings